Biovitrum expands Kineret licence
This article was originally published in Scrip
Executive Summary
Biovitrum of Sweden has expanded its licence agreement with Amgen concerning the interleukin-1 receptor antagonist Kineret (anakinra) to include certain undisclosed orphan indications.